A PHASE 3, PROSPECTIVE, RANDOMIZED, CONTROLLED, OPEN-LABEL, MULTICENTER, 2-PERIOD CROSSOVER STUDY WITH A SINGLE ARM CONTINUATION EVALUATING THE SAFETY AND EFFICACY OF BAX930 (RADAMTS13) IN PROPHYLACTIC AND ON-DEMAND TREATMENT OF SUBJECTS WITH SEVERE CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA (CTTP, UPSHAW-SCHULMAN SYNDROME [USS], HEREDITARY THROMBOTIC THROMBOCYTOPENIC PURPURA [HTTP])

Registry ID

281102

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

BAXALTA INNOVATIONS GMBH

Last update

2017-09-29

Conditions

• UPSHAW-SCHULMAN SYNDROME
• THROMBOTIC THROMBOCYTOPENIC PURPURA

Related clinical trials

• AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAPLACIZUMAB AND IMMUNOSUPPRESSIVE THERAPY WITHOUT FIRST-LINE THERAPEUTIC PLASMA EXCHANGE IN ADULTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
• "A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT."

View on source registry